Quarterly report pursuant to Section 13 or 15(d)

Business (Details)

v3.19.1
Business (Details)
 3 Months Ended
Mar. 31, 2019
USD ($)
product
$ / shares
shares
Mar. 31, 2018
USD ($)
Dec. 31, 2018
USD ($)
Subsequent Event [Line Items]      
Number of marketed medical devices | product 1    
Net loss $ (7,454,048) $ (3,882,847)  
Cash flows from operations (3,121,552) (280,423)  
Accumulated deficit (105,672,118)   $ (98,218,070)
Cash and cash equivalents $ 16,121,388 $ 2,523,927 $ 10,646,301
Neurological Clinical and Preclinical Stage Compounds      
Subsequent Event [Line Items]      
Number of products in development | product 2    
Three Preclinical Therapies      
Subsequent Event [Line Items]      
Number of products in development | product 3    
Preclinical Pediatric Orphan Rare Disease Compound      
Subsequent Event [Line Items]      
Number of products in development | product 1    
Common stock | Underwritten Public Offering      
Subsequent Event [Line Items]      
Number of shares issued in transaction (in shares) | shares 1,818,182    
Sale of stock, price (in dollars per share) | $ / shares $ 5.50    
Net proceeds from sale of stock $ 9,000,000    
Armistice | Common stock | Underwritten Public Offering      
Subsequent Event [Line Items]      
Number of shares issued in transaction (in shares) | shares 363,637